Loading clinical trials...

Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies | Clinical Trials | Clareo Health

RECRUITINGNA

Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies

Repetitive Transcranial Alternating Current Stimulation(rtACS) for the Treatment of Optic Neuropathies

NCT07145073•National Taiwan University Hospital

View on ClinicalTrials.gov

Summary

The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participant must be at least 18.
•2. Clinical diagnosis of glaucoma, with Humphrey Visual Field 24-2 mean deviation (MD) between -22 dB and -5 dB, and Visual Field Index (VFI) between 10% and 90%. The visual field test at screening must meet the following reliability indices:
•* Fixation losses (FL) ≤ 33%
•* False-negative rate (FNR) ≤ 20%
•* False-positive rate (FPR) ≤ 20% At initial screening, the difference in MD between two consecutive visual field tests must be less than 2 dB.
•3. Best-corrected visual acuity (BCVA) ≥ 0.2 in the worse eye selected for stimulation treatment.
•4. If a participant has two eyes meeting study criteria, one eye will be randomly selected by computer for study participation.
•5. In the opinion of the investigator the participant's eye pressure must be clinically stable.
•6. Participant must has the ability to comply with the requirements of the study and complete the schedule of events.
•7. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
+1 more criteria

Exclusion Criteria

•1. History of ocular herpes.
•2. Pathological nystagmus.
•3. Retinal disease sufficient to affect vision.
•4. Corneal opacity affecting vision.
•5. Cataract affecting vision.
•6. Uveitis or other intraocular inflammatory disease.
•7. Implanted electronic devices such as a pacemaker.
•8. Rheumatologic or autoimmune disease.
•9. Brain tumor or intracranial magnetic metallic implants.
•10. History of epilepsy.
+9 more criteria

Locations (1)

National Taiwan University Hospital

Taipei, Hawaii, Taiwan

Key Dates

Start Date

January 26, 2026

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2028

Last Updated

January 30, 2026

Enrollment

188

ESTIMATED participants

Conditions

Glaucoma

Interventions

DC-Stimulator MC

DEVICE

DC-Stimulator MC

DEVICE

Contacts

Chien-Chia Su

CONTACT

+886 972653340 chienchiasu@ntu.edu.tw

Yu-Cen Ma

CONTACT

s431075656@gmail.com

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545

GlaucomaOcular Surface Disease

View study

RECRUITINGNA

Automated Applanation Tonometry - Updated

NCT07298356

GlaucomaGlaucoma, Suspect

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies

Inclusion Criteria

Exclusion Criteria

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Automated Applanation Tonometry - Updated

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye

Efficacy and Safety of Tran Cannula in Combined Pseudoexfoliative Glaucoma and Cataract Surgery Compared With Augmented Ocular Irrigation

DSLT for Reducing Medication in Glaucoma

Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt